Market capitalization | $123.42m |
Enterprise Value | $48.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.67 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-29.49m |
Free Cash Flow (TTM) Free Cash Flow | $-19.57m |
Cash position | $74.88m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Atossa Genetics Inc. forecast:
4 Analysts have issued a Atossa Genetics Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.03 -0.03 |
200%
200%
|
|
EBITDA | -29 -29 |
3%
3%
|
EBIT (Operating Income) EBIT | -29 -29 |
3%
3%
|
Net Profit | -27 -27 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Steven Quay |
Employees | 12 |
Founded | 2008 |
Website | www.atossatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.